Publications by authors named "Ji Sang Ryu"
Article Synopsis
- Enoxaparin, a medication used to treat blood clots, is dosed based on actual body weight, but its effectiveness can vary in obese patients due to distribution differences related to body composition.
- The study evaluated dosing strategies and monitored Antifactor Xa (AFXa) levels in obese patients receiving enoxaparin, reviewing data from 762 patients over a year.
- Results showed no significant link between dosing and AFXa levels, and the rates of treatment failure (2.2%) and bleeding (5%) were comparable to general expectations, indicating that obesity did not independently impact treatment outcomes.
Objective: This review aims to systematically summarize the available data on efficacy and safety of therapeutic enoxaparin in obese patients and to identify gaps to guide future research.
Data Sources: Medline and Embase were systematically searched for eligible studies (last searched December 20, 2023). Studies were included if they reported on therapeutic dosing regimens, adverse bleeding, thrombotic outcomes, or antifactor Xa (AFXa) monitoring in obese adult patients.